SEARCH

SEARCH BY CITATION

References

  • Attal, M., Blaise, D., Marit, G., Payen, C., Michallet, M., Vernant, J.P., Sauvage, C., Troussard, X., Nedellec, G. & Pico, J. (1995) Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood, 86, 16191628.
  • Bruggemann, M., Raff, T., Flohr, T., Gokbuget, N., Nakao, M., Droese, J., Luschen, S., Pott, C., Ritgen, M., Scheuring, U., Horst, H.A., Thiel, E., Hoelzer, D., Bartram, C.R. & Kneba, M. (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood, 107, 11161123.
  • Cave, H., Van Der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group. The New England Journal of Medicine, 339, 591598.
  • Chim, J.C., Coyle, L.A., Yaxley, J.C., Cole-Sinclair, M.F., Cannell, P.K., Hoffbrand, V.A. & Foroni, L. (1996) The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL. British Journal of Haematology, 92, 104115.
  • Coustan-Smith, E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.C., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 26912696.
  • Van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., Van Wering, E.R., Ludwig, W.D., Basso, G., De Bruijn, M.A., Cazzaniga, G., Hettinger, K., Van Der Does-van den Berg, A., Hop, W.C., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 17311738.
  • Dworzak, M.N., Froschl, G., Printz, D., Mann, G., Potschger, U., Muhlegger, N., Fritsch, G. & Gadner, H. (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood, 99, 19521958.
  • Eckert, C., Scrideli, C.A., Taube, T., Songia, S., Wellmann, S., Manenti, M., Seeger, K., Biondi, A. & Cazzaniga, G. (2003) Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes. Leukemia, 17, 25172524.
  • Fielding, A.K., Richards, S.M., Chopra, R., Lazarus, H.M., Litzow, M.R., Buck, G., Durrant, I.J., Luger, S.M., Marks, D.I., Franklin, I.M., McMillan, A.K., Tallman, M.S., Rowe, J.M. & Goldstone, A.H. (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 109, 944950.
  • Goldstone, A.H., Richards, S.M., Lazarus, H.M., Tallman, M.S., Buck, G., Fielding, A.K., Burnett, A.K., Chopra, R., Wiernik, P.H., Foroni, L., Paietta, E., Litzow, M.R., Marks, D.I., Durrant, J., McMillan, A., Franklin, I.M., Luger, S., Ciobanu, N. & Rowe, J.M. (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 111, 18271833.
  • Hunault, M., Harousseau, J.L., Delain, M., Truchan-Graczyk, M., Cahn, J.Y., Witz, F., Lamy, T., Pignon, B., Jouet, J.P., Garidi, R., Caillot, D., Berthou, C., Guyotat, D., Sadoun, A., Sotto, J.J., Lioure, B., Casassus, P., Solal-Celigny, P., Stalnikiewicz, L., Audhuy, B., Blanchet, O., Baranger, L., Bene, M.C. & Ifrah, N. (2004) Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood, 104, 30283037.
  • Knechtli, C.J., Goulden, N.J., Hancock, J.P., Grandage, V.L., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 40724079.
  • Miglino, M., Berisso, G., Grasso, R., Canepa, L., Clavio, M., Pierri, I., Pietrasanta, D., Gatto, S., Varaldo, R., Ballerini, F., Verdiani, S., Casarino, L., DeStefano, F., Sessarego, M., Dominietto, A., Raiola, A.M., Bregante, S., Di Grazia, C., Gobbi, M. & Bacigalupo, A. (2002) Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplantation, 30, 579585.
  • Mizuta, S., Ito, Y., Kohno, A., Kiyoi, H., Miyamura, K., Tanimoto, M., Takamatsu, J., Naoe, T., Morishima, Y., Ueda, R. & Saito, H. (1999) Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Bone Marrow Transplantation, 24, 777784.
  • Moorman, A.V., Harrison, C.J., Buck, G.A., Richards, S.M., Secker-Walker, L.M., Martineau, M., Vance, G.H., Cherry, A.M., Higgins, R.R., Fielding, A.K., Foroni, L., Paietta, E., Tallman, M.S., Litzow, M.R., Wiernik, P.H., Rowe, J.M., Goldstone, A.H. & Dewald, G.W. (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 109, 31893197.
  • Mortuza, F.Y., Papaioannou, M., Moreira, I.M., Coyle, L.A., Gameiro, P., Gandini, D., Prentice, H.G., Goldstone, A., Hoffbrand, A.V. & Foroni, L. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 10941104.
  • Nakao, M., Janssen, J.W., Flohr, T. & Bartram, C.R. (2000) Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Research, 60, 32813289.
  • Nyvold, C., Madsen, H.O., Ryder, L.P., Seyfarth, J., Svejgaard, A., Clausen, N., Wesenberg, F., Jonsson, O.G., Forestier, E. & Schmiegelow, K. (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood, 99, 12531258.
  • Pongers-Willemse, M.J., Seriu, T., Stolz, F., D’Aniello, E., Gameiro, P., Pisa, P., Gonzalez, M., Bartram, C.R., Panzer-Grumayer, E.R., Biondi, A., San Miguel, J.F. & Van Dongen, J.J. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 110118.
  • Ribera, J.M., Ortega, J.J., Oriol, A., Fontanillas, M., Hernandez-Rivas, J.M., Brunet, S., Garcia-Conde, J., Maldonado, J., Zuazu, J., Gardella, S., Besalduch, J., Leon, P., Macia, J., Domingo-Albos, A., Feliu, E. & San Miguel, J.F. (1998) Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica, 83, 222230.
  • Rowe, J.M., Buck, G., Burnett, A.K., Chopra, R., Wiernik, P.H., Richards, S.M., Lazarus, H.M., Franklin, I.M., Litzow, M.R., Ciobanu, N., Prentice, H.G., Durrant, J., Tallman, M.S. & Goldstone, A.H. (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 106, 37603767.
  • Sanchez, J., Serrano, J., Gomez, P., Martinez, F., Martin, C., Madero, L., Herrera, C., Garcia, J.M., Casano, J. & Torres, A. (2002) Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology, 116, 686694.
  • Sebban, C., Lepage, E., Vernant, J.P., Gluckman, E., Attal, M., Reiffers, J., Sutton, L., Racadot, E., Michallet, M., Maraninchi, D., Dreyfus, F. & Fiere, D. (1994) Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 12, 25802587.
  • Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., Zanotti, M.C., Oldani, E., Grassi, A., Intermesoli, T., Mico, C., Rossi, G., Fabris, P., Lambertenghi-Deliliers, G., Angelucci, E., Barbui, T., Bassan, R. & Rambaldi, A. (2007) Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica, 92, 612618.
  • Szczepanski, T., Langerak, A.W., Wolvers-Tettero, I.L., Ossenkoppele, G.J., Verhoef, G., Stul, M., Petersen, E.J., De Bruijn, M.A., Van’t Veer, M.B. & Van Dongen, J.J. (1998) Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease. Leukemia, 12, 10811088.
  • Thomas, X., Boiron, J.M., Huguet, F., Dombret, H., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., Vernant, J.P., Tournilhac, O., Buzyn, A., Reman, O., Charrin, C., Boucheix, C., Gabert, J., Lheritier, V. & Fiere, D. (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. Journal of Clinical Oncology, 22, 40754086.
  • Tiley, C., Powles, R., Treleaven, J., Catovsky, D., Milan, S., Teo, C.P., Catalano, J., Mehta, J., Shields, M. & Gupta, P. (1993) Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow Transplantation, 12, 449455.
  • Uckun, F.M., Kersey, J.H., Haake, R., Weisdorf, D., Nesbit, M.E. & Ramsay, N.K. (1993) Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. The New England Journal of Medicine, 329, 12961301.
  • Van Der Velden, V., Willemse, M.J., Van Der Schoot, C.E., Hahlen, K., Van Wering, E.R. & Van Dongen, J.J. (2002) Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia, 16, 928936.
  • Van Der Velden, V., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., Zur, S.U., Beldjord, K., Raff, T., Van Der Schoot, C.E. & Van Dongen, J.J. (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 21, 604611.
  • Vidriales, M.B., Perez, J.J., Lopez-Berges, M.C., Gutierrez, N., Ciudad, J., Lucio, P., Vazquez, L., Garcia-Sanz, R., Del Canizo, M.C., Fernandez-Calvo, J., Ramos, F., Rodriguez, M.J., Calmuntia, M.J., Porwith, A., Orfao, A. & San Miguel, J.F. (2003) Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood, 101, 46954700.